Regeneron Reports 10% Decline in Q1 2026 Net Income to $727 Million
Regeneron Pharmaceuticals reported a 10% decline in GAAP net income to $727 million for Q1 2026 compared to Q1 2025. However, non-GAAP net income increased by 12% to $1.04 billion. The company also saw a 19% rise in total revenue to $3.6 billion, driven by growth in collaboration revenue and other income.
Topics: Collaboration Revenue Drug Pricing Agreement Earnings Per Share Net Income R&D Expenses Revenue Growth